← Back to Search

18F-rhPSMA-7.3 PET/MRI for Prostate Cancer Active Surveillance

Q: Are individuals under 30 years of age being included in the current research study?

This trial has an age range of 18-89, and is thus available to adult patients.

Q: Is it still possible to submit an application for this research study?

According to the information provided on clinicaltrials.gov, recruiting for this medical trial has ceased. Having been first posted in March of 2023 and last updated January 21st, it is among a pool of 1,294 other trials currently searching for enrollees.

Q: Is participation in this experiment feasible for me?

Currently, this clinical trial is searching for 30 male individuals with <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> between 18 and 89 years old. The specific inclusion criteria are as follows: Men who have had a biopsy that confirms low risk or favourable intermediate risk prostate cancer, scheduled to undergo multiparametric <a href="https://www.withpower.com/clinical-trials/mri">MRI</a> scans followed by confirmatory biopsies in accordance with institutional active surveillance protocols.

Phase < 1

Recruiting

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, average 1 year

Awards & highlights

Study Summary

This trial studies how PET/MRI with an imaging drug and MRI contrast can help diagnose prostate cancer in those eligible for active surveillance. Not a treatment trial.

Who is the study for?

This trial is for men with low risk or favorable intermediate risk prostate cancer confirmed by biopsy, who are following an active surveillance protocol that includes MRI and a confirmatory biopsy. It's not suitable for those without histological confirmation of prostate cancer, previous treatments for it, inability to undergo MRI due to claustrophobia or incompatible devices, or if they don't meet the criteria for active surveillance.Check my eligibility

What is being tested?

The study is testing the effectiveness of a new imaging technique using PET/MRI scans combined with an investigational radioactive drug called 18F-rhPSMA-7.3 and MRI contrast agents. This research aims to improve how doctors monitor prostate cancer in patients who are under active surveillance.See study design

What are the potential side effects?

Since this study focuses on imaging rather than treatment, side effects may be related to the PET/MRI procedure or the investigational drug used during scanning. These could include allergic reactions to contrast agents, discomfort from lying still during imaging, and exposure to radiation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, average 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, average 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, average 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of lesions detected in total on the participants' mpMRI exams.

Secondary outcome measures

Number of lesions detected on the participants' 18F-rhPSMA-7.3 exams.

Other outcome measures

Number of malignant lesions identified on PET/MRI-guided targeted biopsy

Number of malignant lesions identified on mpMRI-guided targeted biopsy

Trial Design

1Treatment groups

Experimental Treatment

Group I: Prostate CancerExperimental Treatment1 Intervention

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,432 Total Patients Enrolled

10 Trials studying Prostate Cancer

2,717 Patients Enrolled for Prostate Cancer

Media Library

Prostate Cancer Clinical Trial Eligibility Overview. Trial Name: NCT05707182 — Phase < 1

Prostate Cancer Research Study Groups: Prostate Cancer

Prostate Cancer Clinical Trial 2023: Prostate Cancer Highlights & Side Effects. Trial Name: NCT05707182 — Phase < 1

Prostate Cancer 2023 Treatment Timeline for Medical Study. Trial Name: NCT05707182 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals under 30 years of age being included in the current research study?

"This trial has an age range of 18-89, and is thus available to adult patients."

Answered by AI

Is it still possible to submit an application for this research study?

"According to the information provided on clinicaltrials.gov, recruiting for this medical trial has ceased. Having been first posted in March of 2023 and last updated January 21st, it is among a pool of 1,294 other trials currently searching for enrollees."

Answered by AI

Is participation in this experiment feasible for me?

"Currently, this clinical trial is searching for 30 male individuals with prostate cancer between 18 and 89 years old. The specific inclusion criteria are as follows: Men who have had a biopsy that confirms low risk or favourable intermediate risk prostate cancer, scheduled to undergo multiparametric MRI scans followed by confirmatory biopsies in accordance with institutional active surveillance protocols."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study

Samuel Joseph Galgano 2025. "18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05707182.